Chronic, bolus administration of D-threo methylphenidate

Abstract

Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.

What is claimed is:  
     
         1 . A method of treating at least one of attention deficit disorder, attention deficit hyperactivity disorder, or AIDS-related dementia, comprising the chronic administration of D-threo methylphenidate or a pharmaceutically acceptable salt thereof, substantially free of both L-threo methylphenidate and erythro methylphenidates, said administration comprising a single, bolus dosage of said D-threo methylphenidate in each twenty-four hour period.  
     
     
         2 . The method of  claim 1  wherein said bolus dosages are administered orally.  
     
     
         3 . The method of  claim 1  wherein said bolus dosages are administered by injection or infusion.  
     
     
         4 . The method of  claim 1  wherein said dosages are administered each morning.  
     
     
         5 . The method of  claim 1  wherein said bolus dosage is from about 0.01 mg/kg to about 1 mg/kg of patient body weight.  
     
     
         6 . The method of  claim 1  wherein said bolus dosage is from about 0.1 mg/kg to about 0.5 mg/kg of patient body weight.  
     
     
         7 . The method of  claim 1  wherein said administration is of D-threo methylphenidate hydrochloride.  
     
     
         8 . The method of  claim 1  wherein said bolus dosage further comprises a pharmaceutically acceptable carrier.  
     
     
         9 . The method of  claim 1  wherein said chronic administration gives rise to efficacious treatment of the disorder without interfering with patient sleep patterns or engendering anoretic behavior.  
     
     
         10 . A method of reversing an effect of a phenidate drug comprising administering to a patient having a serum level of said drug L-threo methylphenidate or a pharmaceutically effective salt thereof.  
     
     
         11 . A drug dosage form comprising D-threo methylphenidate or a pharmaceutically effective salt thereof in an amount effective for once daily, bolus administration to a patient in order to engender treatment for a nervous disorder for substantially an entire day on a chronic basis.